SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

2019572 citationsJournal Articlegold Open Access

Authors

Chenguang Li · Tianjin Medical University

Jie Zhang · Tianjin Medical University

Mei Xue · Tianjin Medical University

Xiaoyu Li · Tianjin Medical University

Fei Han · Tianjin Medical University

Xiangyang Liu · Tianjin Medical University

Linxin Xu ·

Abstract

Glycaemic control with empagliflozin significantly ameliorated myocardial oxidative stress injury and cardiac fibrosis in diabetic mice. Taken together, these results indicate that the empagliflozin is a promising agent for the prevention and treatment of diabetic cardiomyopathy.

Topics & Keywords

Diabetes Treatment and Management Cardiovascular Function and Risk Factors Adenosine and Purinergic Signaling

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cardiovascular Diabetology

Volume 18, Issue 1, pp. 15-15

DOI: 10.1186/s12933-019-0816-2

Field-Weighted Citation Impact: 40.62